亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice

医学 睾酮(贴片) 雄激素剥夺疗法 雄激素 临床实习 游离睾酮 内科学 内分泌学 泌尿科 性激素结合球蛋白 激素 物理疗法 前列腺癌 癌症
作者
Rashid K. Sayyid,Abdallah Sayyid,Zachary Klaassen,Kamel Fadaak,Hanan Goldberg,Thenappan Chandrasekar,Ardalan E. Ahmad,Ricardo Leão,Nathan Perlis,Karen Chadwick,Robert J. Hamilton,Girish S. Kulkarni,Antonio Finelli,Alexandre R. Zlotta,Neil Fleshner
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:199 (1): 251-256 被引量:5
标识
DOI:10.1016/j.juro.2017.07.078
摘要

No AccessJournal of UrologyAdult Urology1 Jan 2018Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice Rashid K. Sayyid, Abdallah K. Sayyid, Zachary Klaassen, Kamel Fadaak, Hanan Goldberg, Thenappan Chandrasekar, Ardalanejaz Ahmad, Ricardo Leao, Nathan Perlis, Karen Chadwick, Robert J. Hamilton, Girish S. Kulkarni, Antonio Finelli, Alexandre R. Zlotta, and Neil E. Fleshner Rashid K. SayyidRashid K. Sayyid Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada Department of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia More articles by this author , Abdallah K. SayyidAbdallah K. Sayyid Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Zachary KlaassenZachary Klaassen Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada Department of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia More articles by this author , Kamel FadaakKamel Fadaak Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Hanan GoldbergHanan Goldberg Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Thenappan ChandrasekarThenappan Chandrasekar Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Ardalanejaz AhmadArdalanejaz Ahmad Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Ricardo LeaoRicardo Leao Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Nathan PerlisNathan Perlis Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Karen ChadwickKaren Chadwick Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Robert J. HamiltonRobert J. Hamilton Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Girish S. KulkarniGirish S. Kulkarni Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Antonio FinelliAntonio Finelli Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author , Alexandre R. ZlottaAlexandre R. Zlotta Department of Urology, Mt. Sinai Hospital, Toronto, Ontario, Canada More articles by this author , and Neil E. FleshnerNeil E. Fleshner Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.07.078AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determined whether men on continuous androgen deprivation therapy who achieve testosterone less than 0.7 nmol/l demonstrate subsequent testosterone elevations during followup and whether such events predict worse oncologic outcomes. Materials and Methods: We evaluated a random, retrospective sample of 514 patients with prostate cancer treated with continuous androgen deprivation therapy in whom serum testosterone was less than 0.7 nmol/l at University Health Network between 2007 and 2016. Patients were followed from the date of the first testosterone measurement of less than 0.7 nmol/l to progression to castrate resistance, death or study period end. Study outcomes were the development of testosterone elevations greater than 0.7, greater than 1.1 and greater than 1.7 nmol/l, and progression to a castrate resistant state. Survival curves were constructed to determine the rate of testosterone elevations. Multivariate Cox regression analysis was done to assess whether elevations predicted progression to castrate resistance. Results: Median patient age was 74 years and median followup was 20.3 months. Within 5 years of followup 82%, 45% and 18% of patients had subsequent testosterone levels greater than 0.7, greater than 1.1 and greater than 1.7 nmol/l, respectively. In 96% to 100% of these patients levels less than 0.7 nmol/l were subsequently reestablished within 5 years. No patient baseline characteristic was associated with elevations and elevations were not a significant predictor of progression to a castrate resistant state. Conclusions: Men on continuous androgen deprivation therapy in whom initial testosterone is less than 0.7 nmol/l frequently show subsequent elevations in serum testosterone. Such a development should not trigger an immediate response from physicians as these events are prognostically insignificant with regard to oncologic outcomes. Levels are eventually reestablished at less than 0.7 nmol/l. References 1 : Role of luteinising hormone releasing hormone (LHRH) agonist in the management of prostate cancer. Eur Urol2005; 4: 4. Google Scholar 2 : Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate—1941. J Urol2002; 168: 9. Link, Google Scholar 3 : EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol2014; 65: 467. Google Scholar 4 : EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol2017; 71: 630. Google Scholar 5 : Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin. Clin Chem1987; 33: 1372. Google Scholar 6 : Reassessment of the definition of castrate levels of testosterone: implications for clinical decision-making. Urology2000; 56: 1021. Crossref, Medline, Google Scholar 7 : Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol2007; 178: 1290. Link, Google Scholar 8 : Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol2015; 33: 1151. Google Scholar 9 : Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int2009; 103: 322. Google Scholar 10 : Free testosterone during androgen deprivation therapy predicts castration-resistant progression better than total testosterone. Prostate2007; 77: 114. Google Scholar © 2018 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byTremblay S, Summers-Trasiewicz L, Pouliot F, Crook J, Ding K, Klotz L and Toren P (2021) Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate CancerJournal of Urology, VOL. 206, NO. 5, (1166-1176), Online publication date: 1-Nov-2021.Saad F, Fleshner N, Pickles T, Niazi T, Lukka H, Pouliot F, Martins I and Klotz L (2020) Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate CancerJournal of Urology, VOL. 204, NO. 3, (416-426), Online publication date: 1-Sep-2020.Taneja S (2017) Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerJournal of Urology, VOL. 199, NO. 1, (26-28), Online publication date: 1-Jan-2018. Volume 199Issue 1January 2018Page: 251-256Supplementary Materials Advertisement Copyright & Permissions© 2018 by American Urological Association Education and Research, Inc.Keywordsandrogen antagonistsprostatic neoplasmstestosteronecastrationprognosisMetricsAuthor Information Rashid K. Sayyid Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada Department of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia More articles by this author Abdallah K. Sayyid Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Zachary Klaassen Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada Department of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, Georgia More articles by this author Kamel Fadaak Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Hanan Goldberg Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Thenappan Chandrasekar Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Ardalanejaz Ahmad Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Ricardo Leao Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Nathan Perlis Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Karen Chadwick Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Robert J. Hamilton Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Girish S. Kulkarni Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Antonio Finelli Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Alexandre R. Zlotta Department of Urology, Mt. Sinai Hospital, Toronto, Ontario, Canada More articles by this author Neil E. Fleshner Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada More articles by this author Expand All Advertisement PDF downloadLoading ...
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
量子星尘发布了新的文献求助10
4秒前
6秒前
souther完成签到,获得积分0
7秒前
深情安青应助lf采纳,获得10
20秒前
青树柠檬完成签到 ,获得积分10
21秒前
24秒前
32秒前
lf发布了新的文献求助10
35秒前
38秒前
43秒前
45秒前
安安发布了新的文献求助10
48秒前
优美的谷完成签到,获得积分10
51秒前
52秒前
哈哈完成签到 ,获得积分10
52秒前
Hshi完成签到 ,获得积分10
57秒前
Alex完成签到,获得积分0
58秒前
安安完成签到,获得积分10
1分钟前
欧阳完成签到 ,获得积分10
1分钟前
cherlie应助带虾的烧麦采纳,获得10
1分钟前
Ava应助科研通管家采纳,获得10
1分钟前
1分钟前
骆十八完成签到,获得积分10
1分钟前
狸宝的小果子完成签到 ,获得积分10
1分钟前
wanci应助义气的蝴蝶采纳,获得10
1分钟前
Xiaowen完成签到,获得积分10
1分钟前
酷炫的红牛完成签到,获得积分10
1分钟前
jll完成签到 ,获得积分10
1分钟前
逮劳完成签到 ,获得积分10
1分钟前
维维完成签到 ,获得积分10
1分钟前
隐形曼青应助Xiaowen采纳,获得10
1分钟前
2分钟前
量子星尘发布了新的文献求助10
2分钟前
WittingGU完成签到,获得积分0
2分钟前
kdjm688发布了新的文献求助30
2分钟前
2分钟前
yujie完成签到,获得积分10
2分钟前
2分钟前
思源应助孙孙采纳,获得50
2分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976608
求助须知:如何正确求助?哪些是违规求助? 3520720
关于积分的说明 11204567
捐赠科研通 3257359
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806613